Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

RBD Dimer recombinant protein vaccine against SARSCoV2

Project description

Innovative platform for the recombinant vaccines against COVID-19 variants

The EU-funded RBDCOV project aims to test two new vaccines against the Wuhan and South African/United Kingdom variants of SARS-CoV-2 using data on the application of recombinant protein developed by the project partners. The project will include a Phase I/II clinical trial of the Wuhan vaccine for the paediatric population and Phase I/II of adjuvant recombinant receptor-binding domain (RBD) protein of South African/United Kingdom variants for booster vaccination in adults. Monitoring of the new emerging variants will be performed to ensure platform readiness. The platform for the vaccines is adaptable and will be ready to include in the design the future new variants. The RBDCOV consortium will have the opportunity to generate the first RBD recombinant vaccine to be approved in Europe.

Objective

The main objective of RBDCOV project is to test the efficacy, tolerability, and safety of a new vaccine against different variants of COVID-19 based on the outstanding data generated using a recombinant protein developed by the consortium partners. Two different clinical trials will be run during the project duration to test the variants recombinant RBD protein vaccine, codifying for Beta and Alpha SARS-Cov-2 variants in paediatric population and in immunocompromised adults.

The aim of the project is to focus not only on the current SARS-CoV-2 variants but also in the emerging ones as Beta and Alpha variants. Thus, a continuous monitoring of the new emerging variants will be performed throughout the project to ensure that the platform is prepared to cope with the disease. The platform used for the generation of the vaccines is adaptable to variants and will be ready to include in the design any other potential variant that could appear in short, medium and large term. Preclinical data are already available.

The core of RBDCOV consortium has been in close contact to the corresponding agencies and considering Reflection paper on the regulatory requirements for vaccines intended to provide protection against variant strain(s) of SARS-CoV-2, preclinical data supporting the first vaccine candidate can be extrapolated for the vaccines against the new emerging variants. This create a unique opportunity for RBDCOV consortium to generate the first RBD recombinant vaccine to be approved in Europe. This vaccine will be manufactured by an European technological company that will change actual paradigms and allow the really change to One health concept, based on the close relationship between the animal world and the onset of certain infections in humans.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) HORIZON-HLTH-2021-CORONA-01

See all projects funded under this call

Coordinator

HIPRA SCIENTIFIC SL
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 1 096 898,79
Address
AVINGUDA LA SELVA 135
17170 Amer
Spain

See on map

Region
Este Cataluña Girona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 1 895 348,58

Participants (19)

My booklet 0 0